1.Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; ...
[15] Krop I E, Kim S B, Martin A G, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival r...
The five year overall survival rate for HER2-enriched cases was 100%, for Luminal-HER2 cases 80%, for Luminal A cases 80%, for Luminal B cases 55%, and for Triple-negative cases 0%. Of the 16 HER2 positive cases (Luminal-HER2 and HER2 enriched), there was only one death at 48.4 ...
2022年1月13日,《美国医学会杂志》肿瘤学分册在线发表意大利米兰大学欧洲癌症研究院、美国哈佛大学医学院达纳法伯癌症研究所、布莱根医院和波士顿妇女医院的述评,对HER2阳性晚期乳腺癌个体化治愈方法进行了系统回顾。 许多临床特征和病理特征可使医师能够识别出更有可能对化疗和HER...
The HER2-positive patients were more likely to be grade 2, ER negative, and were more likely to have received chemotherapy. Table 1 Clinicopathological details Full size table Human epidermal growth factor receptor 2 status and survival Sixty-one percent of cases were HER2 positive. In univariate...
[1] Bingfeng Han,et al.(2024).Cancer incidence and mortality in China,2022. Journal of the National Cancer Center. [2] Fehm T,etal.Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): ...
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study ...
1.Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82. 2.Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical...
2022年1月13日,《美国医学会杂志》肿瘤学分册在线发表意大利米兰大学欧洲癌症研究院、美国哈佛大学医学院达纳法伯癌症研究所、布莱根医院和波士顿妇女医院的述评,对HER2阳性晚期乳腺癌个体化治愈方法进行了系统回顾。 这群患者可能对德喜曲妥珠单抗、图卡替尼或马吉妥昔单抗等新型抗HER2药物的个体化升级一线治疗获益。近年...
多中心的Ⅲ期临床试验,主要研究终点为研究者(investigator,INV)评估的无进展生存期(progression-free survival,PFS),次要研究终点包括独立评审委员会(Independent Review Committee,IRC)评估的PFS、总生存期(overall survival,OS)、客观缓解率(objective response rate...